Revolution Medicines

The FDA has issued a “safe to proceed” letter allowing Revolution Medicines to initiate an expanded access treatment protocol (EAP) for our investigational RAS(ON) multi-selective inhibitor in patients with previously treated metastatic pancreatic ductal adenocarcinoma (PDAC).    Read our statement here: https://lnkd.in/dJUQRY8F

Our team walked with Pancreatic Cancer Action Network at PurpleStride, standing alongside patients, families, caregivers, survivors, and advocates united by shared purpose and commitment to advancing pancreatic cancer treatment.    As a proud national sponsor and long-term partner to the pancreatic cancer community, we are driven by our mission: revolutionizing treatment for patients with pancreatic cancer and other RAS-driven cancers.     This progress is only possible because of this community's courage, resilience, and advocacy. We are deeply grateful to PanCAN and everyone here for your partnership, trust, and leadership.   Progress is about people. We're honored to stand with you and drive this work forward together.    #PanCANPurpleStride 

We presented preclinical data highlighting an innovative new class of mutant-targeted catalytic RAS(ON) inhibitors at the American Association for Cancer Research Annual Meeting. In preclinical models, an oral compound with this mechanism as the primary driver of RAS pathway inhibition drove deep and durable tumor regressions across multiple tumor types and overcame resistance to prior RAS inhibition. Read the full release: https://lnkd.in/g82adzhA #AACR26

Today at the American Association for Cancer Research Annual Meeting, we announced updated clinical data from two Phase 1/2 trials evaluating our RAS(ON) multi-selective inhibitor in patients with previously untreated metastatic pancreatic cancer. The data support the continued evaluation in the ongoing Phase 3 RASolute 303 trial across both monotherapy and combination therapy.  Read the full release: https://lnkd.in/ghAMBDSH #AACR26 #PancreaticCancer

Revolution Medicines will present detailed results from the pivotal Phase 3 RASolute 302 clinical trial results during a Plenary Session at the American Society of Clinical Oncology (ASCO) Annual Meeting.     Read the release: https://lnkd.in/gky9WzZJ   #ASCO26

Today we announced updated Phase 1 data for our RAS(ON) G12D-selective inhibitor in patients with previously treated KRAS G12D non-small cell lung cancer at the American Association for Cancer Research Annual Meeting. These updated data further strengthen the profile of our RAS(ON) G12D-selective inhibitor as a potentially important targeted therapy for patients with RAS G12D non-small cell lung cancer, a population with significant unmet medical need. Learn more: https://lnkd.in/gkCPAdWm #AACR26 #LungCancer

Thank you to Drug Hunter for recognizing our investigational RAS(ON) inhibitor as the 2025 Molecule of the Year. This honor reflects our team's commitment to advancing research and innovation in one of cancer research's most formidable challenges. We're dedicated to developing new treatment approaches for patients with RAS-driven cancers.   Read the full announcement: https://lnkd.in/gRcH6x-2

We are pleased to announce an unprecedented overall survival benefit from the Phase 3 RASolute 302 trial evaluating our RAS(ON) multi-selective inhibitor in previously treated metastatic pancreatic cancer. Read the press release: https://lnkd.in/gcijWQ-S    #Oncology #PancreaticCancer 

We’re pleased to share that we have begun treating patients in RASolute 303, our global Phase 3 trial evaluating our investigational therapy as first line treatment for patients with metastatic pancreatic cancer. RASolute 303 is testing two approaches: monotherapy and combination therapy with standard of care chemotherapy.   For patients with metastatic PDAC, a disease where approximately 90% of cases are RAS-driven and nearly 80% are diagnosed at advanced stages, new treatment options are urgently needed.      Learn more: https://lnkd.in/g9VvquXC

Colorectal cancer (CRC) remains one of the most commonly diagnosed cancers in the United States, impacting tens of thousands of patients and families each year. In 2026 alone, it’s expected to account for more than 55,000 deaths, making it the second leading cause of cancer-related mortality.   Approximately 50% of colorectal cancer cases are driven by RAS mutations. Yet patients with RAS mutant CRC continue to experience suboptimal outcomes with current treatment options.   At Revolution Medicines, we're advancing innovative RAS(ON) inhibitors across multiple RAS driven cancers, including CRC, as part of our ongoing commitment to addressing the urgent needs of these patient communities.   Greater awareness, earlier detection and continued scientific innovation are essential to changing the trajectory of this disease.   #ColorectalCancerAwarenessMonth